Lonza Group AG (LZAGY)
USD 64.83
(-1.27%)
USD 64.83
(-1.27%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 1.52 Billion CHF | -11.01% |
| 2022 | 1.08 Billion CHF | -15.74% |
| 2021 | 1.28 Billion CHF | 41.14% |
| 2020 | 909 Million CHF | -27.8% |
| 2019 | 1.25 Billion CHF | 5.36% |
| 2018 | 1.19 Billion CHF | 6.03% |
| 2017 | 1.12 Billion CHF | 29.99% |
| 2016 | 867 Million CHF | 29.21% |
| 2015 | 671 Million CHF | 3.07% |
| 2014 | 651 Million CHF | 13.61% |
| 2013 | 573 Million CHF | -14.48% |
| 2012 | 670 Million CHF | 52.62% |
| 2011 | 439 Million CHF | 30.27% |
| 2010 | 337 Million CHF | 10.13% |
| 2009 | 306 Million CHF | -23.12% |
| 2008 | 398 Million CHF | -1.0% |
| 2007 | 402 Million CHF | 52.85% |
| 2006 | 263 Million CHF | -0.38% |
| 2005 | 264 Million CHF | 3.53% |
| 2004 | 255 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 582 Million CHF | 321.74% |
| 2023 Q2 | 497 Million CHF | 43.64% |
| 2023 FY | 962 Million CHF | -11.01% |
| 2023 Q4 | 138 Million CHF | -72.23% |
| 2022 Q2 | 520 Million CHF | -3.7% |
| 2022 Q4 | 346 Million CHF | -33.46% |
| 2022 FY | 1.08 Billion CHF | -15.74% |
| 2021 Q4 | 540 Million CHF | -26.33% |
| 2021 Q2 | 733 Million CHF | 151.03% |
| 2021 FY | 1.28 Billion CHF | 41.14% |
| 2020 Q2 | 609 Million CHF | -5.43% |
| 2020 FY | 909 Million CHF | -27.8% |
| 2020 Q4 | 292 Million CHF | -52.05% |
| 2019 Q2 | 659 Million CHF | -1.64% |
| 2019 FY | 1.25 Billion CHF | 5.36% |
| 2019 Q4 | 644 Million CHF | -2.28% |
| 2018 Q4 | 670 Million CHF | 10.2% |
| 2018 FY | 1.19 Billion CHF | 6.03% |
| 2018 Q2 | 608 Million CHF | 0.0% |
| 2017 Q4 | - CHF | -100.0% |
| 2017 Q2 | 511 Million CHF | -14.69% |
| 2017 FY | 1.12 Billion CHF | 29.99% |
| 2016 Q4 | 599 Million CHF | 46.1% |
| 2016 Q2 | 410 Million CHF | 0.0% |
| 2016 FY | 867 Million CHF | 29.21% |
| 2015 Q2 | 333 Million CHF | -18.78% |
| 2015 Q4 | 410 Million CHF | 23.12% |
| 2015 FY | 671 Million CHF | 3.07% |
| 2014 Q4 | 410 Million CHF | 23.12% |
| 2014 FY | 651 Million CHF | 13.61% |
| 2014 Q2 | 333 Million CHF | -10.72% |
| 2013 Q4 | 373 Million CHF | -0.53% |
| 2013 Q2 | 375 Million CHF | 0.0% |
| 2013 FY | 573 Million CHF | -14.48% |
| 2012 FY | 670 Million CHF | 52.62% |
| 2012 Q4 | - CHF | 0.0% |
| 2011 Q4 | - CHF | 0.0% |
| 2011 FY | 439 Million CHF | 30.27% |
| 2010 FY | 337 Million CHF | 10.13% |
| 2010 Q4 | - CHF | 0.0% |
| 2009 Q4 | - CHF | 0.0% |
| 2009 FY | 306 Million CHF | -23.12% |
| 2008 FY | 398 Million CHF | -1.0% |
| 2008 Q4 | - CHF | 0.0% |
| 2007 FY | 402 Million CHF | 52.85% |
| 2006 FY | 263 Million CHF | -0.38% |
| 2005 FY | 264 Million CHF | 3.53% |
| 2004 FY | 255 Million CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| American Bio Medica Corporation | 1.04 Million USD | -145085.891% |
| Arrayit Corporation | 6.19 Million USD | -24474.124% |
| Atlantic International Corp. | 5.57 Million USD | -27202.347% |
| Biocept, Inc. | 29.4 Million USD | -5080.096% |
| Bioqual, Inc. | 7.44 Million USD | -20346.326% |
| CardioGenics Holdings Inc | 772.14 Thousand USD | -197143.512% |
| DermTech, Inc. | 104.01 Million USD | -1364.212% |
| Global WholeHealth Partners Corporation | - USD | -Infinity% |
| Hangzhou Tigermed Consulting Co., Ltd. | 166.5 Million USD | -814.708% |
| HTG Molecular Diagnostics, Inc. | 22.62 Million USD | -6631.884% |
| iMD Companies, Inc. | 151.8 Thousand USD | -1003134.327% |
| IDenta Corp. | 662.97 Thousand USD | -229622.086% |
| Interpace Biosciences, Inc. | 20.23 Million USD | -7427.679% |
| Integrative Health Technologies, Inc. | 38.88 Thousand USD | -3916980.322% |
| InVitro International | 661.32 Thousand USD | -230195.589% |
| Lumos Diagnostics Holdings Limited | 7.09 Million USD | -21356.748% |
| Many Bright Ideas Technologies Inc. | 58.11 Thousand USD | -2620701.211% |
| Medical Imaging Corp. | 1.91 Million USD | -79547.98% |
| NovelStem International Corp. | 3.53 Million USD | -42949.365% |
| Optigenex Inc. | 1.28 Million USD | -118157.369% |
| PharmChem, Inc. | 2.93 Million USD | -51857.728% |
| Proteome Sciences plc | 3.26 Million USD | -46503.427% |
| Response Genetics, Inc | 25.31 Million USD | -5915.245% |
| Rennova Health, Inc. | 7.67 Million USD | -19736.45% |
| RushNet, Inc. | 1.78 Million USD | -85016.134% |
| ScreenPro Security Inc. | 3.23 Million USD | -46921.948% |
| Stella Diagnostics Inc. | 11.42 Million USD | -13228.141% |
| StageZero Life Sciences Ltd. | 7.34 Million USD | -20640.796% |
| Todos Medical Ltd. | 14.05 Million USD | -10733.689% |